Revlimid® (lenalidomide) – First-time generic

- On March 7, 2022, Teva launched an AB-rated generic version of Bristol-Myers Squibb's (BMS) Revlimid (lenalidomide) 5 mg, 10 mg, 15 mg and 25 mg capsules.
    - Teva agreed to a limited launch deal with BMS, allowing for production of a small amount -- described as a mid-single-digit percentage of Revlimid's monthly volume. Over time, that percentage increases, reaching 33% of Revlimid's volume by March 2025. Then on January 31, 2026, the limitations end.
    - Dr. Reddy's received FDA approval of an AB-rated generic version of Revlimid 2.5 mg and 20 mg capsules on October 14, 2021. Dr. Reddy's will be able to launch limited quantities of Revlimid 2.5 mg and 20 mg sometime after March 2022.
- Revlimid and generic lenalidomide are both approved for the treatment of adult patients with multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma. Additionally, brand Revlimid is approved for follicular lymphoma and marginal zone lymphoma.
- Revlimid is also available as brand 2.5 mg and 20 mg capsules.
- Revlimid carries a boxed warning for embryo-fetal toxicity, hematologic toxicity, and venous and arterial thromboembolism.
- According to IQVIA, Revlimid had annual sales of $2.3 billion as of December 2021.
- Teva's generic Revlimid will initially be priced about 13.5% lower than BMS's brand Revlimid, approximately about $15,100 per month. Wholesale acquisition cost (WAC) will be about $720 for a capsule of generic Revlimid and $833 for a capsule of brand Revlimid.

At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.

© 2022 Optum, Inc. All rights reserved. ORX6547968A-TEMPLATE_220208